Get the Stockscreener App
4.35
0.69%
0.03
After Hours:
4.43
0.08
+1.84%
Vanda Pharmaceuticals Inc stock is traded at $4.35, with a volume of 1.12M.
It is up +0.69% in the last 24 hours and down -12.83% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$4.32
Open:
$4.36
24h Volume:
1.12M
Relative Volume:
2.07
Market Cap:
$257.04M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
83.02
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-20.91%
1M Performance:
-12.83%
6M Performance:
-3.55%
1Y Performance:
-6.45%
1-Day Range:
$4.28
$4.51
1-Week Range:
$4.28
$5.70
52-Week Range:
$3.8092
$5.70
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.35 | 255.27M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
FY2025 EPS Estimates for VNDA Boosted by Cantor Fitzgerald - MarketBeat
Can Vanda Pharmaceuticals Inc. stock deliver surprise earnings beat2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com
Backtesting results for Vanda Pharmaceuticals Inc. trading strategiesJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Assessing Vanda Pharmaceuticals (VNDA) Valuation After Q3 2025 Growth and Updated FDA Milestones - Yahoo Finance
Visualizing Vanda Pharmaceuticals Inc. stock with heatmapsMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Is Vanda Pharmaceuticals Inc. stock safe for conservative investorsMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
How institutional buying supports Vanda Pharmaceuticals Inc. stock2025 Top Decliners & Smart Swing Trading Techniques - newser.com
News impact scoring models applied to Vanda Pharmaceuticals Inc.July 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress - MSN
Cantor Fitzgerald Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $11.00 - MarketBeat
Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec” - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Published on: 2025-10-31 05:46:53 - newser.com
Applying big data sentiment scoring on Vanda Pharmaceuticals Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Real time pattern detection on Vanda Pharmaceuticals Inc. stockQuarterly Profit Review & Consistent Return Strategy Ideas - newser.com
Vanda Pharmaceuticals Inc. stock retracement – recovery analysis - newser.com
Will Vanda Pharmaceuticals Inc. stock recover after recent dropShare Buyback & Weekly Watchlist for Consistent Profits - newser.com
Can Vanda Pharmaceuticals Inc. recover in the next quarterWeekly Investment Report & Reliable Entry Point Alerts - newser.com
Will Vanda Pharmaceuticals Inc. (VM4) stock remain on Wall Street radarExit Point & Momentum Based Trading Ideas - newser.com
Is Vanda Pharmaceuticals Inc. (VM4) stock considered safe havenBond Market & AI Driven Price Forecasts - newser.com
Smart tools for monitoring Vanda Pharmaceuticals Inc.’s price actionWeekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
How Vanda Pharmaceuticals Inc. stock performs in interest rate cyclesMarket Volume Report & High Win Rate Trade Alerts - newser.com
How supply shortages influence Vanda Pharmaceuticals Inc. (VM4) stock2025 Top Gainers & Verified Entry Point Signals - newser.com
Vanda Pharmaceuticals (VNDA): Forecasts See Earnings Growth of 68.5% Annually Heading Into Earnings Season - Sahm
Vanda Pharmaceuticals (VNDA): Revenue Projected to Grow 22.7% Annually, Profitability in Focus Ahead of Earnings - Yahoo Finance
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc. (VNDA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses - GuruFocus
VNDA Analyst Rating Update: Cantor Fitzgerald Adjusts Price Target | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda: Q3 Earnings Snapshot - CT Insider
Vanda Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vanda Pharmaceuticals Q3 2025 Earnings: EPS of -$0.38 Beats Esti - GuruFocus
Vanda Pharmaceuticals Q3 2025 Earnings: EPS of -$0.38 Beats Estimates, Revenue of $56.3M Misses Expectations - GuruFocus
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - Lelezard
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):